Home/Filings/4/0000950170-25-023569
4//SEC Filing

von Moltke Lisa 4

Accession 0000950170-25-023569

CIK 0001609809other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 8:05 PM ET

Size

13.0 KB

Accession

0000950170-25-023569

Insider Transaction Report

Form 4
Period: 2025-02-15
von Moltke Lisa
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-15+2,96935,384 total
  • Exercise/Conversion

    Common Stock

    2025-02-15+8,90744,291 total
  • Sale

    Common Stock

    2025-02-18$0.81/sh4,416$3,57939,875 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-152,96923,750 total
    Common Stock (2,969 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-02-158,90726,718 total
    Common Stock (8,907 underlying)
Footnotes (5)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  • [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 11, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  • [F3]The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8376, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  • [F5]The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Documents

1 file

Issuer

Seres Therapeutics, Inc.

CIK 0001609809

Entity typeother

Related Parties

1
  • filerCIK 0001808592

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 8:05 PM ET
Size
13.0 KB